Merck stock
Price history
+30.28% over the period1 year: from €115.75 (November 17, 2025) to €150.80 (November 16, 2026), +30.28%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 16, 2026 | €150.80 |
| October 30, 2026 | €151.30 |
| September 30, 2026 | €138.10 |
| August 31, 2026 | €139.00 |
| July 31, 2026 | €143.15 |
| June 30, 2026 | €146.85 |
| May 29, 2026 | €130.85 |
| April 30, 2026 | €110.05 |
| March 31, 2026 | €107.60 |
| February 27, 2026 | €128.30 |
| January 30, 2026 | €125.55 |
| December 30, 2025 | €122.60 |
| November 28, 2025 | €116.00 |
| November 17, 2025 | €115.75 |
At a glance
The company
Science and technology company offering life science products and services, healthcare pharmaceuticals, and advanced materials for electronics and semiconductors
Latest results
Quarter to September 30, 2026 · EPS €2.32 (estimate €2.09)
TickerLandia's take on Merck
- Priced as usual relative to earnings: P/E on the latest fiscal year 25 vs a median of 25 over its last 10 fiscal years.
- Pricier than similar companies: trailing 12-month P/E 34 vs 25 (+35%) in a group of 11.
- Strong point: Market momentum (73/100 in its group). Weak point: Growth (19/100).
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−3.49% from the 52-week high
Analysts · 14 analysts
Average target€156.86+4.02% vs. price
Buy 6 · Hold 8 · Sell 0 · Buy
TickerLandia Fingerprint: Merck
Compared with similar companies: very low growth.
Financials and price compared with 39 companies in the drug manufacturers - specialty & generic industry, worldwide. Momentum and risk compared with 1,160 European stocks.
Priceaverage42
How much it costs relative to what it produces.
Metric Value Position in group P/E (trailing 12 months) 33.8 67 Forward P/E 16.4 35 EV/EBITDA 12.0 29 Price/book 2.07 35 Price/sales 3.03 46 Profitabilitylow28
How much it earns on revenue and capital.
Metric Value Position in group Operating margin 17.0% 37 ROE 6.4% 19 ROA 4.4% 27 Gross margin 59.0% 29 Net margin 8.9% 27 Earnings stabilityhigh70
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 1.9% 78 Loss-making yearscounts in reverse: lower means more earnings stability 0 of 5 annual reports 63 Growthvery low19
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) −1.72% 9 Revenue growth (year over year) +5.80% 33 Earnings growth (year over year) −49.80% 15 Financial strengthaverage42
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Net debt/EBITDAcounts in reverse: lower means more financial strength 1.62 39 Interest coverage 12.1 47 Debt/equitycounts in reverse: lower means more financial strength 0.38 46 Current ratio 1.69 37 Dividendhigh67
How much it returns to shareholders, and for how long.
Metric Value Position in group Dividend yield 1.5% 47 Consecutive dividend years 27 years 80 Payout ratio 49.8% 73 Market momentumstrong73
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) +5.44% 68 Relative strength (6 months) +11.42% 78 Distance from 200-day average +14.55% 79 1-year return +23.18% 67 Riskaverage41
How much the price swings.
Metric Value Position in group Volatility (60 days) 21.7% 27 Maximum drawdown (12 months) 21.7% 40 Beta (1 year) 0.82 56
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
Merck is priced as in the past and pricier than similar companies
On the latest fiscal year's earnings (2025), Merck's P/E today is 25.1, in line with the median of its last 10 fiscal years (25.0; between 15.3 and 36.5 from 2016 to 2025). Merck's P/E (trailing 12 months): 33.8, +35% against the median of a group of 11 similar companies (25.0).
Compared with 11 similar companies
| Metric | Merck | Position in the group | Band |
|---|---|---|---|
| P/E (trailing 12 months) | 33.8 | High | |
| Forward P/E | 16.4 | Middle | |
| Operating margin | 17.0% | Middle | |
| ROE | 6.4% | Low | |
| Debt/equity | 0.38 | Middle |
P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Merck. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€5.63B
Latest quarter · Q3 2026
Net income
€450M
Latest quarter · Q3 2026
Quarterly net margin
8.0%
Latest quarter · Q3 2026
Numbers and valuation
Full valuation- Market cap
- €65.04B
- P/E
- 33.8
- EPS
- €4.42
- Volume
- 283.64K
- Daily trading
- €43.48M
- Dividend yield
- 1.46%
- Last ex-dividend on April 27, 2026
How Merck is changing
All resultsRevenue grew 3.8% a year on average over the last 5 years
Operating margin fell from 22.4% to 18.6%
Free cash flow equal to 88% of net income
Returns
Merck returns with dividends
€1,000 invested in Merck 5 years ago, on November 16, 2021, would be worth €755 today with dividends reinvested: −24.48% in total, −5.46% per year. On price alone it would be €699 (−30.06%).
| Period | Merck | DAX | €1,000 becomes |
|---|---|---|---|
| 1 month | +4.50% | +5.90% | €1,045 |
| 6 months | +28.50% | +11.69% | €1,285 |
| Year to date | +23.00% | +9.23% | €1,230 |
| 1 year | +32.91% | +13.39% | €1,329 |
| 3 years | +2.41% | +69.45% | €1,024 |
| 5 years | −24.48% | +64.64% | €755 |
| 10 years | +83.74% | +150.85% | €1,837 |
Over the last 6 months it has done better than 50% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. DAX: with dividends. Calculate your investment
The chart in detail
Merck: technical analysis
Merck is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 34.3% below its all-time closing high (€229.40, December 28, 2021).
- Trend
- Upward
- RSI (14 sessions)
- 60
- Between 30 and 70
- vs 200-session average
- +15.35%
Support and resistance
Price areas where Merck has stopped several times in the last year. They describe the chart; they are not forecasts.
- No resistance above: the price is near the highs of the year
- Last price€150.80
- Support€148.72−1.38%2 touches, last on August 6, 2026
- Support€141.48−6.18%3 touches, last on October 22, 2026
- Support€132.00−12.47%3 touches, last on October 2, 2026
Volatility and risk
Over the last year it has moved roughly in line with the DAX.
- Beta (1 year) vs DAX
- 0.81
- Volatility (60 sessions, annualised)
- 21.8%
- Largest fall in the last year
- −21.68%
In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
Merck: seasonality
Average monthly price change over 29 years
Over the last 29 years, the strongest month for Merck has been November: +3.31% on average, positive in 20 years out of 28. The weakest has been February: −1.68% on average, positive in 11 years out of 28.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +1.17% | +2.57% | 18 of 28 |
| February | −1.68% | −2.10% | 11 of 28 |
| March | +1.16% | +2.93% | 15 of 28 |
| April | +1.79% | +1.11% | 17 of 28 |
| May | +1.92% | +0.36% | 15 of 28 |
| June | −0.63% | +0.03% | 14 of 28 |
| July | +0.65% | +0.60% | 18 of 29 |
| August | −0.13% | +0.35% | 15 of 29 |
| September | +0.27% | +0.35% | 15 of 29 |
| October | +1.78% | −1.08% | 14 of 29 |
| November | +3.31% | +2.83% | 20 of 28 |
| December | +0.75% | +0.46% | 15 of 28 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
Merck and its competitors
Revenue of EUR 21.1 billion comes from three segments that serve very different customers. Life Science supplies academic, research and diagnostic laboratories, biotech and pharmaceutical companies, and industrial clients with reagents, consumables, lab water instruments and flow cytometry kits, along with bioprocessing products such as chromatography resins and single-use systems, and contract development and manufacturing services. Healthcare develops and sells prescription drugs and biopharmaceuticals for oncology, rare diseases, neurology, immunology, fertility, cardiovascular and metabolic disorders.
- Headquarters
- Darmstadt, Germany
- Employees
- 61,949
- Founded
- 1668
- Chief executive
- Kai Beckmann
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| MerckMRK | $71.89B | 17.0% | 33.8 | +28.50% |
| Galderma GroupGALD | $53.24B | 19.1% | 66.0 | +22.82% |
| Sandoz GroupSDZ | $43.66B | 9.3% | 72.3 | +30.60% |
| HaleonHLN | $40.03B | 23.5% | 19.2 | +4.51% |
| Swedish Orphan BiovitrumSOBI | $16.42B | 30.9% | 25.0 | +8.39% |
| IpsenIPN | $15.16B | 27.4% | 26.9 | +0.60% |
Same industry or related industries, similar size. Compare Merck with its competitors · Full profile
